Properties (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:businessModel |
research and development
partnerships licensing agreements collaborative research biotech startup |
| gptkbp:CEO |
gptkb:Dr._Kevin_D._Williams
|
| gptkbp:clinicalTrials |
gptkb:Asia
gptkb:Canada gptkb:United_States Europe Type 1 diabetes Phase 1 Phase 2 Type 2 diabetes Phase 1/2 clinical trial |
| gptkbp:collaborations |
gptkb:Massachusetts_Institute_of_Technology
biopharmaceutical companies |
| gptkbp:develops |
cell replacement therapies
|
| gptkbp:focusesOn |
diabetes treatment
|
| gptkbp:founded |
2015
|
| gptkbp:founder |
gptkb:Dr._Kevin_D._Williams
|
| gptkbp:goal |
restore insulin production
|
| gptkbp:headquarters |
gptkb:Cambridge,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Semma Therapeutics
|
| gptkbp:innovation |
cell-based therapies
|
| gptkbp:investmentFocus |
$114 million
|
| gptkbp:keyIssues |
stem cell-derived insulin-producing cells
|
| gptkbp:mission |
transform diabetes treatment
|
| gptkbp:partnerships |
gptkb:Harvard_University
gptkb:University_of_Chicago gptkb:American_Diabetes_Association JDRF |
| gptkbp:products |
therapeutic products
commercial products clinical products insulin-producing beta cells |
| gptkbp:regulatoryCompliance |
FDA_approval_process
|
| gptkbp:research |
venture capital
|
| gptkbp:researchAreas |
metabolic disorders
autoimmune diseases |
| gptkbp:researchFocus |
regenerative medicine
|
| gptkbp:researchInterest |
peer-reviewed journals
international research institutions |
| gptkbp:technology |
biomaterials
gene editing cell therapy stem cell technology islet cell transplantation |